Replies to post #16125 on Biotech Values

[DewDiligence]

Re: CYTK

>>Too bad for CYTK's oncology program. But I do think their myosin-targeted drugs for CV disease are much more interesting now than i did 6 months ago.<<

If I recall correctly, I mentioned CYTK as a possible company for IMCL to buy about a year ago, but you dismissed the idea on the IMCL board. Why do you find them so much more interesting now than as recently as six months ago? T.i.a.